However, in view of the fact that CD4+ T cells play a crucial role in optimal tumor-specific CTL activity [34, 35] and are themselves capable of recognizing and controlling melanoma [6, 36–39], it seems unwise to prevent potential CD4+CD25hiFoxP3+ T cell accumulation at the cost of tumor-specific CD4+ T cells. The gene discussed is CD4; the disease is melanoma.